09:19 AM EDT, 07/17/2025 (MT Newswires) -- NervGen Pharma ( NGENF ) on Thursday said President and Chief Executive Mike Kelly reisgned and that Chairman Adam Rogers has been appointed interim CEO.

"We are deeply grateful to Mike for his exceptional leadership during a pivotal time for NervGen," said Rogers. "Under Mike's guidance, the company advanced NVG-291 through landmark proof-of-concept topline results from the chronic cohort of the CONNECT SCI study."

The company said that the leadership transition comes as it continues to analyze data from the chronic cohort of the CONNECT SCI study in preparation for sharing additional insights and engaging in regulatory discussions.